Acumen Pharmaceuticals posts corporate presentation on sabirnetug Alzheimer’s drug candidate

Acumen

Acumen

ABOS

0.00
  • Acumen Pharmaceuticals highlighted sabirnetug (ACU193), an intravenous monoclonal antibody designed to selectively target toxic amyloid beta oligomers in early Alzheimer’s disease.
  • ALTITUDE-AD Phase 2 trial is fully enrolled with 542 patients; topline results expected late 2026.
  • Cash, cash equivalents, marketable securities totaled about $128 million as of March 31, 2026; cash runway expected to extend into early 2027.
  • Program update included EBD enhanced brain delivery platform for oligomer-targeted antibodies using BBB-penetrating technology; preclinical candidate data disclosed early 2026; IND filing targeted for mid-2027.
  • Phase 1 data cited low ARIA-E incidence at about 10%, with no ARIA-E observed in ApoE4 homozygotes in a subgroup of 6 patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.